A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)
Status: Recruiting
Location: See all (36) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ≥18 years of age at the time of consent.
• ECOG performance status of 0 or 1.
• Documented diagnosis of MM per IMWG diagnostic criteria.
• Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.
• Have documented evidence of progressive disease per IMWG criteria.
• Participant must have measurable disease at screening.
• Participant must have adequate bone marrow and organ function (hematological, hepatic and renal) demonstrated at screening.
Locations
United States
Alabama
Research Site
RECRUITING
Birmingham
Arizona
Research Site
RECRUITING
Phoenix
California
Research Site
RECRUITING
La Jolla
Research Site
RECRUITING
Los Angeles
Research Site
RECRUITING
San Francisco
Colorado
Research Site
RECRUITING
Aurora
Research Site
RECRUITING
Denver
Florida
Research Site
RECRUITING
Jacksonville
Research Site
NOT_YET_RECRUITING
Miami
Research Site
RECRUITING
Tampa
Georgia
Research Site
RECRUITING
Atlanta
Iowa
Research Site
RECRUITING
Iowa City
Illinois
Research Site
RECRUITING
Chicago
Massachusetts
Research Site
RECRUITING
Boston
Research Site
RECRUITING
Boston
Michigan
Research Site
NOT_YET_RECRUITING
Ann Arbor
Research Site
RECRUITING
Detroit
Minnesota
Research Site
NOT_YET_RECRUITING
Minneapolis
Research Site
RECRUITING
Rochester
North Carolina
Research Site
NOT_YET_RECRUITING
Charlotte
Research Site
RECRUITING
Durham
Nebraska
Research Site
WITHDRAWN
Omaha
New Jersey
Research Site
WITHDRAWN
Hackensack
New York
Research Site
NOT_YET_RECRUITING
Buffalo
Research Site
RECRUITING
New York
Research Site
RECRUITING
Stony Brook
Tennessee
Research Site
RECRUITING
Nashville
Research Site
RECRUITING
Nashville
Texas
Research Site
RECRUITING
Austin
Research Site
RECRUITING
Dallas
Research Site
RECRUITING
Houston
Utah
Research Site
NOT_YET_RECRUITING
Salt Lake City
Virginia
Research Site
RECRUITING
Charlottesville
Washington
Research Site
RECRUITING
Edmonds
Research Site
RECRUITING
Seattle
Wisconsin
Research Site
RECRUITING
Milwaukee
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2023-07-20
Estimated Completion Date: 2028-11-14
Participants
Target number of participants: 182
Treatments
Experimental: AZD0120
AZD0120 will be administered by infusion
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca